Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives

Matteo R. Pastore, Elena Bazzigaluppi, Riccardo Bonfanti, Nicoletta Dozio, Alessandro Sergi, Annalisa Balini, Cristina Belloni, Franco Meschi, Ezio Bonifacio, Emanuele Bosi

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - To examine the performance of islet cell antibodies (ICAs) and antibodies to glutamate decarboxylase (GADA), IA-2 (IA-2 antibody [IA- 2A]), and insulin (insulin autoantibody [IAA]), alone and in combination, in assessing type 1 diabetes risk within type 1 diabetic families to identify a practical and effective screening strategy for predicting type 1 diabetes in relatives. RESEARCH DESIGN AND METHODS - ICA, GADA, IA-2A, and IAA were determined in 806 first-degree relatives participating in a prospective type 1 diabetes family study (median follow-up 6.17 years, range 0.6-8.3). The conferred risk of developing type I diabetes within 6 years was evaluated by Kaplan-Meier for each antibody marker, used alone or in combination. RESULTS - ICAs were detected in 3%, GADA in 5.1%, IA-2A in 2.5%, and IAA in 3.7% of relatives; ≤ 1 antibody markers were detected in 10.7% of relatives and ≤2 were detected in 1.9% of relatives. The risk of type 1 diabetes at 6 years was 1.5% in relatives with only 1 marker and 24.8% in relatives with ≤2 markers. As a practical and effective strategy for type 1 diabetes risk assessment in relatives, this study indicates a first-step screening based on GADA and IA2A measurement-which identified 6.5% of relatives, including all who developed the disease, with a 6-year type 1 diabetes risk of 9.0%- followed by a second step based on ICA and IAA measurement in relatives with either GADA or IA-2A, which identified a total of 1.9% of all relatives as having ≤2 markers, and a 6-year risk of 24.8%, including 6 of 7 who developed type 1 diabetes. CONCLUSIONS - A two-step antibody screening, based first on GADA and IA-2A and then on ICA and IAA measurements in identified individuals, is likely to be a practical, sensitive, and effective strategy for predicting type 1 diabetes in first-degree relatives.

Original languageEnglish
Pages (from-to)1445-1450
Number of pages6
JournalDiabetes Care
Volume21
Issue number9
Publication statusPublished - 1998

Fingerprint

Type 1 Diabetes Mellitus
Autoantibodies
Glutamate Decarboxylase
Insulin
Antibodies
Research Design
islet cell antibody

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Pastore, M. R., Bazzigaluppi, E., Bonfanti, R., Dozio, N., Sergi, A., Balini, A., ... Bosi, E. (1998). Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. Diabetes Care, 21(9), 1445-1450.

Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. / Pastore, Matteo R.; Bazzigaluppi, Elena; Bonfanti, Riccardo; Dozio, Nicoletta; Sergi, Alessandro; Balini, Annalisa; Belloni, Cristina; Meschi, Franco; Bonifacio, Ezio; Bosi, Emanuele.

In: Diabetes Care, Vol. 21, No. 9, 1998, p. 1445-1450.

Research output: Contribution to journalArticle

Pastore, MR, Bazzigaluppi, E, Bonfanti, R, Dozio, N, Sergi, A, Balini, A, Belloni, C, Meschi, F, Bonifacio, E & Bosi, E 1998, 'Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives', Diabetes Care, vol. 21, no. 9, pp. 1445-1450.
Pastore MR, Bazzigaluppi E, Bonfanti R, Dozio N, Sergi A, Balini A et al. Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. Diabetes Care. 1998;21(9):1445-1450.
Pastore, Matteo R. ; Bazzigaluppi, Elena ; Bonfanti, Riccardo ; Dozio, Nicoletta ; Sergi, Alessandro ; Balini, Annalisa ; Belloni, Cristina ; Meschi, Franco ; Bonifacio, Ezio ; Bosi, Emanuele. / Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives. In: Diabetes Care. 1998 ; Vol. 21, No. 9. pp. 1445-1450.
@article{7405eea852ea4876b79bd1d1180485af,
title = "Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives",
abstract = "OBJECTIVE - To examine the performance of islet cell antibodies (ICAs) and antibodies to glutamate decarboxylase (GADA), IA-2 (IA-2 antibody [IA- 2A]), and insulin (insulin autoantibody [IAA]), alone and in combination, in assessing type 1 diabetes risk within type 1 diabetic families to identify a practical and effective screening strategy for predicting type 1 diabetes in relatives. RESEARCH DESIGN AND METHODS - ICA, GADA, IA-2A, and IAA were determined in 806 first-degree relatives participating in a prospective type 1 diabetes family study (median follow-up 6.17 years, range 0.6-8.3). The conferred risk of developing type I diabetes within 6 years was evaluated by Kaplan-Meier for each antibody marker, used alone or in combination. RESULTS - ICAs were detected in 3{\%}, GADA in 5.1{\%}, IA-2A in 2.5{\%}, and IAA in 3.7{\%} of relatives; ≤ 1 antibody markers were detected in 10.7{\%} of relatives and ≤2 were detected in 1.9{\%} of relatives. The risk of type 1 diabetes at 6 years was 1.5{\%} in relatives with only 1 marker and 24.8{\%} in relatives with ≤2 markers. As a practical and effective strategy for type 1 diabetes risk assessment in relatives, this study indicates a first-step screening based on GADA and IA2A measurement-which identified 6.5{\%} of relatives, including all who developed the disease, with a 6-year type 1 diabetes risk of 9.0{\%}- followed by a second step based on ICA and IAA measurement in relatives with either GADA or IA-2A, which identified a total of 1.9{\%} of all relatives as having ≤2 markers, and a 6-year risk of 24.8{\%}, including 6 of 7 who developed type 1 diabetes. CONCLUSIONS - A two-step antibody screening, based first on GADA and IA-2A and then on ICA and IAA measurements in identified individuals, is likely to be a practical, sensitive, and effective strategy for predicting type 1 diabetes in first-degree relatives.",
author = "Pastore, {Matteo R.} and Elena Bazzigaluppi and Riccardo Bonfanti and Nicoletta Dozio and Alessandro Sergi and Annalisa Balini and Cristina Belloni and Franco Meschi and Ezio Bonifacio and Emanuele Bosi",
year = "1998",
language = "English",
volume = "21",
pages = "1445--1450",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives

AU - Pastore, Matteo R.

AU - Bazzigaluppi, Elena

AU - Bonfanti, Riccardo

AU - Dozio, Nicoletta

AU - Sergi, Alessandro

AU - Balini, Annalisa

AU - Belloni, Cristina

AU - Meschi, Franco

AU - Bonifacio, Ezio

AU - Bosi, Emanuele

PY - 1998

Y1 - 1998

N2 - OBJECTIVE - To examine the performance of islet cell antibodies (ICAs) and antibodies to glutamate decarboxylase (GADA), IA-2 (IA-2 antibody [IA- 2A]), and insulin (insulin autoantibody [IAA]), alone and in combination, in assessing type 1 diabetes risk within type 1 diabetic families to identify a practical and effective screening strategy for predicting type 1 diabetes in relatives. RESEARCH DESIGN AND METHODS - ICA, GADA, IA-2A, and IAA were determined in 806 first-degree relatives participating in a prospective type 1 diabetes family study (median follow-up 6.17 years, range 0.6-8.3). The conferred risk of developing type I diabetes within 6 years was evaluated by Kaplan-Meier for each antibody marker, used alone or in combination. RESULTS - ICAs were detected in 3%, GADA in 5.1%, IA-2A in 2.5%, and IAA in 3.7% of relatives; ≤ 1 antibody markers were detected in 10.7% of relatives and ≤2 were detected in 1.9% of relatives. The risk of type 1 diabetes at 6 years was 1.5% in relatives with only 1 marker and 24.8% in relatives with ≤2 markers. As a practical and effective strategy for type 1 diabetes risk assessment in relatives, this study indicates a first-step screening based on GADA and IA2A measurement-which identified 6.5% of relatives, including all who developed the disease, with a 6-year type 1 diabetes risk of 9.0%- followed by a second step based on ICA and IAA measurement in relatives with either GADA or IA-2A, which identified a total of 1.9% of all relatives as having ≤2 markers, and a 6-year risk of 24.8%, including 6 of 7 who developed type 1 diabetes. CONCLUSIONS - A two-step antibody screening, based first on GADA and IA-2A and then on ICA and IAA measurements in identified individuals, is likely to be a practical, sensitive, and effective strategy for predicting type 1 diabetes in first-degree relatives.

AB - OBJECTIVE - To examine the performance of islet cell antibodies (ICAs) and antibodies to glutamate decarboxylase (GADA), IA-2 (IA-2 antibody [IA- 2A]), and insulin (insulin autoantibody [IAA]), alone and in combination, in assessing type 1 diabetes risk within type 1 diabetic families to identify a practical and effective screening strategy for predicting type 1 diabetes in relatives. RESEARCH DESIGN AND METHODS - ICA, GADA, IA-2A, and IAA were determined in 806 first-degree relatives participating in a prospective type 1 diabetes family study (median follow-up 6.17 years, range 0.6-8.3). The conferred risk of developing type I diabetes within 6 years was evaluated by Kaplan-Meier for each antibody marker, used alone or in combination. RESULTS - ICAs were detected in 3%, GADA in 5.1%, IA-2A in 2.5%, and IAA in 3.7% of relatives; ≤ 1 antibody markers were detected in 10.7% of relatives and ≤2 were detected in 1.9% of relatives. The risk of type 1 diabetes at 6 years was 1.5% in relatives with only 1 marker and 24.8% in relatives with ≤2 markers. As a practical and effective strategy for type 1 diabetes risk assessment in relatives, this study indicates a first-step screening based on GADA and IA2A measurement-which identified 6.5% of relatives, including all who developed the disease, with a 6-year type 1 diabetes risk of 9.0%- followed by a second step based on ICA and IAA measurement in relatives with either GADA or IA-2A, which identified a total of 1.9% of all relatives as having ≤2 markers, and a 6-year risk of 24.8%, including 6 of 7 who developed type 1 diabetes. CONCLUSIONS - A two-step antibody screening, based first on GADA and IA-2A and then on ICA and IAA measurements in identified individuals, is likely to be a practical, sensitive, and effective strategy for predicting type 1 diabetes in first-degree relatives.

UR - http://www.scopus.com/inward/record.url?scp=17144475242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144475242&partnerID=8YFLogxK

M3 - Article

C2 - 9727889

AN - SCOPUS:17144475242

VL - 21

SP - 1445

EP - 1450

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -